4,5-epoxy-17-methyl-morphinane-3,6-diol | 509-60-4

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: 4,5-epoxy-17-methyl-morphinane-3,6-diol
• 英文别名: 4,5-Epoxy-17-methyl-morphinan-3,6-diol；14-OH-Dihydroisomorphin；Dihydromorphin；Hydromorphine；3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol
• CAS: 509-60-4；13004-73-4；26626-12-0
• 化学式: C₁₇H₂₁NO₃
• 分子量: 287.359
• InChiKey: IJVCSMSMFSCRME-UHFFFAOYSA-N

物化性质

• 熔点：
  225 °C
• 沸点：
  475.4±45.0 °C(Predicted)
• 密度：
  1.40±0.1 g/cm3(Predicted)
• 溶解度：
  DMF：20mg/mL； DMF:PBS(pH 7.2)(1:1)：0.5 mg/ml；二甲基亚砜：10mg/mL
• 保留指数：
  2450;2451;2467;2451

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  52.9
• 氢给体数：
  2
• 氢受体数：
  4

ADMET

代谢

帕莫芬是二氢可待因的一个已知人体代谢物。

Paramorfan is a known human metabolite of dihydrocodeine.

来源:NORMAN Suspect List Exchange

安全信息

• 海关编码：
  2939190022

文献信息

• One Pot Process for Producing 6-Hydroxyl Nal-Opiate
  申请人：Mallinckrodt LLC

  公开号：US20130203999A1

  公开（公告）日：2013-08-08

  The present invention provides processes for preparing nal-opiates without the isolation of intermediates. In general, the process provides for alkylation and reduction in the same pot to give the nal-opiate.

  本发明提供了一种制备纳洛酮类药物的方法，无需分离中间体。一般来说，该方法在同一容器中进行烷基化和还原反应，从而得到纳洛酮类药物。
• Process for the Preparation of 6-Beta Hydroxy Morphinan Compounds
  申请人：Bao Jian

  公开号：US20090312552A1

  公开（公告）日：2009-12-17

  The invention provides processes for the conversion of a 6-keto morphinan to a 6-hydroxy morphinan. In particular, the invention provides a stereoselective process for the conversion of a 6-keto morphinan to a 6-beta-hydroxy morphinan.

  该发明提供了将6-酮吗啡烷转化为6-羟基吗啡烷的过程。具体地，该发明提供了一种立体选择性的过程，用于将6-酮吗啡烷转化为6-β-羟基吗啡烷。
• Multi-arm polymer prodrugs
  申请人：Zhao Xuan

  公开号：US20080194612A1

  公开（公告）日：2008-08-14

  Provided herein are water-soluble prodrugs. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.

  本文提供了一种水溶性的前药。该发明的前药包括一个水溶性聚合物，具有三个或更多的臂，其中至少三个臂与活性剂（例如小分子）共价连接。本发明的结合物提供了聚合物大小和结构的最佳平衡，以实现改善药物负载，因为本发明的结合物具有三个或更多的活性剂可释放地连接到多臂水溶性聚合物上。本发明的前药具有治疗效果，并在体内表现出比未修改的母体药物更好的性能。
• Multi-Arm Polymer Prodrugs
  申请人：Zhao Xuan

  公开号：US20090074704A1

  公开（公告）日：2009-03-19

  Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.

  本文提供了水溶性前药、包含这种前药的组合物以及相关的制备和使用方法。本发明的前药包括具有三个或更多臂的水溶性聚合物，其中至少三个臂通常共价地连接到一个活性剂，例如小分子。本发明的共轭物提供了聚合物尺寸和结构的最佳平衡，以实现改进的药物装载，因为本发明的共轭物具有三个或更多的活性剂可释放地连接到多臂水溶性聚合物上。本发明的前药具有治疗效果，并且与未经修改的母药相比，在体内表现出改进的性质。
• MULTI-ARM POLYMER PRODRUGS
  申请人：Zhao Xuan

  公开号：US20100190933A1

  公开（公告）日：2010-07-29

  Provided herein are water-soluble prodrugs. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.

  本文提供的是水溶性前药。该发明的前药包括具有三个或更多臂的水溶性聚合物，其中至少三个臂与活性剂（例如小分子）共价连接。本发明的结合物提供了最佳的聚合物大小和结构平衡，以达到改进药物负载的目的，因为本发明的结合物具有三个或更多活性剂可释放地附着于多臂水溶性聚合物上。本发明的前药在治疗上是有效的，并且与未经修改的原始药物相比，在体内表现出改进的性质。

表征谱图